These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Epitope peptide vaccine with oncoantigen for cancer and its biomarker]. Hazama S; Maeda K; Oka M Nihon Rinsho; 2012 Dec; 70(12):2189-93. PubMed ID: 23259395 [TBL] [Abstract][Full Text] [Related]
7. [Tumor vaccine for breast cancer]. Wada H Nihon Rinsho; 2000 Apr; 58 Suppl():352-6. PubMed ID: 11026018 [No Abstract] [Full Text] [Related]
8. Interpreting cancer vaccine clinical trials. Dranoff G J Gene Med; 1999; 1(2):80-3. PubMed ID: 10738571 [TBL] [Abstract][Full Text] [Related]
12. Cancer vaccines: what do we need to measure in clinical trials? Kudrin A Hum Vaccin Immunother; 2014; 10(11):3236-40. PubMed ID: 25483508 [TBL] [Abstract][Full Text] [Related]
13. Tumor antigens as surrogate markers and targets for therapy and vaccines. Dalgleish A; Pandha H Adv Cancer Res; 2007; 96():175-90. PubMed ID: 17161680 [TBL] [Abstract][Full Text] [Related]
14. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy. Seremet T; Brasseur F; Coulie PG Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282 [TBL] [Abstract][Full Text] [Related]
15. Cancer vaccine strategies get bigger and better. de Gruijl TD; Curiel DT Nat Med; 1999 Oct; 5(10):1124-5. PubMed ID: 10502808 [No Abstract] [Full Text] [Related]
16. Lessons learned from cancer vaccine trials and target antigen choice. Butterfield LH Cancer Immunol Immunother; 2016 Jul; 65(7):805-12. PubMed ID: 26842127 [TBL] [Abstract][Full Text] [Related]